Crinetics appoints James Hassard as Chief Commercial Officer

Crinetics Pharmaceuticals, Inc.

James Hassard appointed CCO effective Feb 28, 2022; base salary $425,000, target bonus 40%.
Will receive option to purchase 160,000 shares (25% vest Feb 28, 2023; balance monthly over 3 years).
Hassard brings 30+ years biotech commercial experience; previously CCO at Arrowhead Pharma.
Initial focus on paltusotine Phase 3 PATHFNDR program for acromegaly registration.
Also overseeing commercial readiness for pipeline candidates CRN04777 and CRN04894.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James Hassard

Chief Commercial Officer

CRNX · Crinetics Pharmaceuticals, Inc.

Effective: 2022-02-28
Filed: March 1, 2022, 6:59 PM ET

On March 1, 2022, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of James Hassard as the Company’s Chief Commercial Officer, which was effective as of February 28, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Hassard was appointed as Chief Commercial Officer at Crinetics Pharmaceuticals, Inc..

Action: appointed
Role: Chief Commercial Officer

Exact text from the filing

On March 1, 2022, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of James Hassard as the Company’s Chief Commercial Officer, which was effective as of February 28, 2022.

View on SEC.gov

Crinetics Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-002421

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.